Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family and has recently been shown to exert tumoricidal activity in vivo in the absence of any observable toxicity. The signaling pathways triggered by TRAIL stimulation and the mechanisms involv...

Full description

Saved in:
Bibliographic Details
Main Authors: Walczak, Henning (Author) , Krammer, Peter H. (Author)
Format: Article (Journal)
Language:English
Published: June 1, 2000
In: Cancer research
Year: 2000, Volume: 60, Issue: 11, Pages: 3051-3057
ISSN:1538-7445
Online Access:Verlag, lizenzpflichtig, Volltext: https://cancerres.aacrjournals.org/content/60/11/3051
Get full text
Author Notes:Henning Walczak, Axel Bouchon, Heiko Stahl, and Peter H. Krammer

MARC

LEADER 00000caa a2200000 c 4500
001 1756018987
003 DE-627
005 20230428043124.0
007 cr uuu---uuuuu
008 210427s2000 xx |||||o 00| ||eng c
035 |a (DE-627)1756018987 
035 |a (DE-599)KXP1756018987 
035 |a (OCoLC)1341406158 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Walczak, Henning  |d 1966-  |e VerfasserIn  |0 (DE-588)172932513  |0 (DE-627)697859703  |0 (DE-576)133786773  |4 aut 
245 1 0 |a Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells  |c Henning Walczak, Axel Bouchon, Heiko Stahl, and Peter H. Krammer 
246 3 3 |a Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-x L-overexpressing chemotherapy-resistant tumor cells 
264 1 |c June 1, 2000 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.04.2021 
500 |a Der Buchstabe "L" im Ausdruck "Bcl-xL" ist im Titel tiefgestellt 
520 |a Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family and has recently been shown to exert tumoricidal activity in vivo in the absence of any observable toxicity. The signaling pathways triggered by TRAIL stimulation and the mechanisms involved in resistance against TRAIL-mediated apoptosis are still poorly defined. We show here that TRAIL-induced apoptosis involves late dissipation of mitochondrial membrane potential (ΔΨm) and cytochrome c release. These events follow activation of caspase-8 and caspase-3 and induction of DNA fragmentation. In addition, caspase-8-deficient cells are resistant against TRAIL-induced apoptosis, and inhibition of caspase-8 but not caspase-9 prevents mitochondrial permeability transition and apoptosis. In contrast, various Bcl-2- or Bcl-xL-overexpressing tumor cell lines are sensitive to TRAIL-induced apoptosis; however, they show a delay in TRAIL-induced mitochondrial permeability transition compared with control transfectants. This indicates that TRAIL-induced apoptosis depends on caspase-8 activation rather than on the disruption of mitochondrial integrity. Because most chemotherapeutic drugs used in the treatment of malignancies lead to apoptosis primarily by engagement of the mitochondrial proapoptotic machinery, we tested whether drug-resistant tumor cells retain sensitivity for TRAIL-induced apoptosis. Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide. However, these cells are not protected or are only marginally protected against TRAIL-induced apoptosis. Thus, TRAIL may still kill tumors that have acquired resistance to chemotherapeutic drugs by overexpression of Bcl-2 or Bcl-x<sub>L</sub>. These data will influence future treatment strategies involving TRAIL. 
700 1 |a Krammer, Peter H.  |d 1946-  |e VerfasserIn  |0 (DE-588)121766373  |0 (DE-627)081520255  |0 (DE-576)292873417  |4 aut 
773 0 8 |i Enthalten in  |t Cancer research  |d Philadelphia, Pa. : AACR, 1941  |g 60(2000), 11, Seite 3051-3057  |h Online-Ressource  |w (DE-627)325489955  |w (DE-600)2036785-5  |w (DE-576)094502226  |x 1538-7445  |7 nnas  |a Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells 
773 1 8 |g volume:60  |g year:2000  |g number:11  |g pages:3051-3057  |g extent:7  |a Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells 
856 4 0 |u https://cancerres.aacrjournals.org/content/60/11/3051  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210427 
993 |a Article 
994 |a 2000 
998 |g 121766373  |a Krammer, Peter H.  |m 121766373:Krammer, Peter H.  |d 50000  |e 50000PK121766373  |k 0/50000/  |p 4  |y j 
998 |g 172932513  |a Walczak, Henning  |m 172932513:Walczak, Henning  |d 50000  |e 50000PW172932513  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1756018987  |e 391816344X 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","display":"Walczak, Henning","roleDisplay":"VerfasserIn","given":"Henning","family":"Walczak"},{"given":"Peter H.","family":"Krammer","role":"aut","display":"Krammer, Peter H.","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells","title":"Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells"}],"recId":"1756018987","language":["eng"],"note":["Gesehen am 27.04.2021","Der Buchstabe \"L\" im Ausdruck \"Bcl-xL\" ist im Titel tiefgestellt"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-x L-overexpressing chemotherapy-resistant tumor cells"}],"name":{"displayForm":["Henning Walczak, Axel Bouchon, Heiko Stahl, and Peter H. Krammer"]},"id":{"eki":["1756018987"]},"origin":[{"dateIssuedKey":"2000","dateIssuedDisp":"June 1, 2000"}],"relHost":[{"origin":[{"publisherPlace":"Philadelphia, Pa.","dateIssuedDisp":"1941-","publisher":"AACR","dateIssuedKey":"1941"}],"id":{"zdb":["2036785-5"],"eki":["325489955"],"issn":["1538-7445"]},"name":{"displayForm":["American Association for Cancer Research"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Cancer research","title":"Cancer research"}],"pubHistory":["Volume 1, issue 1 (1 January 1941)-"],"part":{"issue":"11","pages":"3051-3057","year":"2000","extent":"7","text":"60(2000), 11, Seite 3051-3057","volume":"60"},"disp":"Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cellsCancer research","note":["Gesehen am 31.03.25","Fortsetzung der Druck-Ausgabe"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Association for Cancer Research"}],"recId":"325489955"}],"physDesc":[{"extent":"7 S."}]} 
SRT |a WALCZAKHENTUMORNECRO1200